What is the role of the Forrest classification in guiding proton pump inhibitor (PPI) therapy for a patient with a bleeding peptic ulcer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Forrest Classification and PPI Therapy in Bleeding Peptic Ulcers

Role of Forrest Classification in Guiding PPI Therapy

The Forrest classification directly determines both the need for endoscopic intervention and the intensity of PPI therapy, with high-risk lesions (Forrest Ia, Ib, IIa, and IIb) requiring immediate endoscopic hemostasis followed by high-dose intravenous PPI (80 mg bolus + 8 mg/hour infusion for 72 hours), while low-risk lesions (Forrest IIc and III) require only standard oral PPI therapy without endoscopic intervention. 1

Forrest Classification Categories and Management

High-Risk Lesions Requiring Aggressive Therapy

  • Forrest Ia (Spurting arterial bleeding): Highest rebleeding risk at 59%, requires immediate dual-modality endoscopic hemostasis plus high-dose IV PPI 2, 3, 4

  • Forrest Ib (Oozing bleeding): Paradoxically has lower rebleeding risk than Forrest IIa and IIb lesions despite active bleeding, but still requires endoscopic therapy and high-dose PPI 1, 4

  • Forrest IIa (Visible vessel): High rebleeding risk requiring endoscopic hemostasis and high-dose PPI, with Doppler studies showing higher arterial flow than Forrest Ib lesions 1, 4

  • Forrest IIb (Adherent clot): Requires vigorous irrigation for at least 5 minutes to expose underlying stigmata; if high-risk stigmata are revealed (occurs in 70% of successfully dislodged clots), treat with endoscopic therapy and high-dose PPI 5, 4

Low-Risk Lesions Requiring Medical Therapy Only

  • Forrest IIc (Flat pigmented spot): Does not require endoscopic hemostasis; manage with standard oral PPI therapy, though patients with Rockall score ≥6 have increased rebleeding risk (18.6% vs 2.9%) and warrant closer monitoring 5, 6

  • Forrest III (Clean base): Lowest rebleeding risk at 5%, requires only standard oral PPI without endoscopic intervention 5, 4

PPI Regimen Based on Forrest Classification

For High-Risk Lesions (Forrest Ia, Ib, IIa, IIb)

  • Initiate PPI therapy as soon as possible, ideally before endoscopy 1, 7

  • After successful endoscopic hemostasis, administer 80 mg IV bolus followed by 8 mg/hour continuous infusion for 72 hours, which reduces rebleeding from 10.3% to 5.9% (p=0.03) and decreases need for repeat endoscopy 1, 7

  • Transition to oral PPI 40 mg twice daily for days 4-14, which reduces rebleeding risk by 63% compared to once-daily dosing (RR 0.37, CI 0.19-0.73) 8

  • Continue oral PPI 40 mg once daily for total duration of 6-8 weeks following endoscopic treatment 1, 8

For Low-Risk Lesions (Forrest IIc, III)

  • Standard oral PPI therapy (20-40 mg once daily) for 6-8 weeks is sufficient without high-dose IV regimen 5, 8

  • Early discharge is appropriate for patients with low-risk lesions and no comorbidities 5

Critical Limitations of Forrest Classification

  • Doppler probe assessment is superior to Forrest classification for predicting rebleeding risk, with Doppler-guided hemostasis reducing 30-day rebleeding rates (NNT=7) 1, 9

  • The Forrest classification has significant intra- and inter-observer variability, limiting its reliability, particularly for duodenal ulcers compared to gastric ulcers 2, 9

  • Forrest Ib lesions have lower rebleeding risk than Forrest IIa and IIb despite representing active bleeding, highlighting that the classification does not perfectly correlate with rebleeding risk 1

  • The Forrest classification does not predict mortality, only rebleeding risk, so clinical factors (Rockall score) must be incorporated for comprehensive risk assessment 6, 2

Common Pitfalls to Avoid

  • Never use epinephrine injection alone for high-risk lesions—it must be combined with mechanical or thermal therapy, as monotherapy provides suboptimal efficacy 5

  • Do not aggressively mechanically dislodge Forrest IIb clots—use cautious irrigation-based approaches for at least 5 minutes, as aggressive dislodgment increases perforation risk 1, 5

  • Do not skip endoscopy in favor of PPI therapy alone for high-risk lesions—PPI is adjunctive therapy, not a replacement for endoscopic hemostasis 7

  • Do not discharge patients with high-risk lesions before 72 hours—60-76% of rebleeding episodes occur within this timeframe 8

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Endoscopic Diagnosis, Grading, and Treatment of Bleeding Peptic Ulcer Disease.

Gastrointestinal endoscopy clinics of North America, 2024

Guideline

Endoscopic Hemostasis for Peptic Ulcer with Adherent Clot

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

PPI Drip Regimen for Bleeding Peptic Ulcers

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Stomach Ulcers

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the Forrest classification of gastrointestinal (GI) bleeding?
What is the Forrest classification for bleeding gastric ulcers and its management?
What is the Forrest classification for gastric ulcers?
What is the therapeutic management for each Forrest stage of bleeding ulcers?
What is the Forrest classification of bleeding peptic ulcers?
Can a patient with a severe bacterial infection on the left tonsil, presenting with visible grey exudate/pus and a foul odor, and being treated with clindamycin (due to penicillin (pcn) allergy) 300mg orally (po) three times a day (tid) for 10 days, have a sexually transmitted disease (STD) as the cause of infection, given no culture is available?
What are the recommended medications for a patient with constipation, considering their potential gastrointestinal disorders and other medications?
What could be the reason for inadequate blood glucose control in a patient taking metformin (2g/day), glimepiride (2mg/day), vildagliptin (100mg/day), Lantus (22 units) (insulin glargine), and regular insulin (20 units before lunch and dinner) with pre-lunch and pre-dinner blood glucose levels of 281mg/dL and 393mg/dL?
How to clinically diagnose and manage heart failure in an adult patient with a history of hypertension, diabetes, or coronary artery disease, presenting with symptoms such as shortness of breath, fatigue, and swelling in the legs, without access to 2D (two-dimensional) echo?
What is the appropriate evaluation and management approach for a patient presenting with nontraumatic leg pain, considering their age, occupation, activity level, past medical history, allergies, medications, and social history?
Can Subacute Sclerosing Panencephalitis (SSPE) be caused by the Measles, Mumps, and Rubella (MMR) vaccine?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.